Aucta Pharmaceuticals China
Shanghai
About Aucta Pharmaceuticals China
Aucta is a pharmaceutical company that uses the 505(b)(2) regulatory pathway to create better products from proven molecules. Aucta is developing new therapeutics through innovation, including new dosage forms, dosing regimens, and indications. It develops and commercializes branded specialty products as well as technology platform-based niche generics. Aucta's therapeutic focus is on CNS disorders, Ophthalmics, and Inhalation Therapy. We are committed to being patient-centric by bringing improved versions of proven molecules to market regularly.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $15.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2021)
- Website: auctapharma.com
- Phone: +86 21 58585606
Industries & Categories
Health Care
Social Profiles
Canonical: https://fsome.com/organization/aucta-pharmaceuticals-china-146095 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.